Articles tagged with Neurodegenerative Diseases
Researchers have identified a panel of key proteins in blood that can predict the emergence of ALS symptoms months to years before they arise. This discovery could enable early intervention with preventative therapies.
A study found that brain immune cells undergo substantial remodeling in midlife, leading to chronic neuroinflammation and potential dementia risk. The research used advanced single-cell analysis techniques to analyze postmortem hippocampal tissue from 40 healthy adults.
Researchers developed a new methodology using artificial intelligence to analyze brain electrical activity during sleep, identifying early neural alterations and classifying patients into distinct biological subgroups. This non-invasive approach may facilitate earlier diagnosis of Alzheimer's disease.
Researchers identify a specialized lymphatic network in the brain that enables cerebrospinal fluid drainage, which declines with age but can be restored through intranasal VEGF-C delivery. This discovery provides new insights into brain waste clearance and its link to neurodegenerative disorders.
Researchers found that bee venom can improve motor function and cognitive decline in a mouse model of Parkinson's disease when used alongside conventional therapy. The study suggests promising benefits for developing adjunct therapies to improve treatment outcomes.
A new study by Sanford Burnham Prebys found that bolstering the SORLA protein can reduce tau tangle toxicity, a common culprit in Alzheimer's disease and other neurodegenerative disorders. This suggests potential as a therapeutic strategy for treating these conditions.
Researchers found that tau buildup in PSP affects brain networks involved in thinking, including the prefrontal cortex and anterior cingulate cortex. The study suggests that symptoms arise from both local tau-related damage and remote disruption of a broader cognitive network.
Researchers at Kyoto University discovered an RNA aptamer, 1R6, that targets the disordered regions of alpha-synuclein protein, inhibiting its aggregation and promoting disassembly of pre-existing aggregates. This finding offers a new therapeutic strategy for neurodegenerative disorders like Parkinson's disease.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A blood test measuring phosphorylated tau 217 (P-tau217) can estimate an individual's risk of developing cognitive impairment over 2, 5, and 10 years. Higher P-tau217 levels are associated with increased risk of progression to cognitive impairment in cognitively unimpaired older adults.
Researchers discovered that reducing microglial activity worsened abnormal electrical activity and increased seizure-like events in a mouse model of Alzheimer's disease. Microglia are not just drivers of inflammation but also perform important housekeeping functions to maintain healthy brain activity.
A scoping review suggests astrocytic dysfunction may precede neuronal degeneration in CTE. Astrocytes' dysregulation contributes to the development of CTE's characteristic features through mechanisms including astrogliosis, disrupted waste clearance pathways, and chronic neuroinflammation.
The University of Cincinnati launches the Center for Alzheimer's and Neurodegenerative Diseases Research (CANDR) to improve dementia prevention and treatment outcomes. CANDR aligns with UC's mission to innovate and engage locally while addressing one of the region's most pressing public health challenges.
A University of Houston chemist is uncovering how copper imbalances in neurons contribute to neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. The new imaging technique provides a closer look at individual protein behaviors inside living cells, giving researchers insight into the cellular pathways that fail.
A new study published in the Journal of Alzheimer's Disease estimates that dementia-related costs across 30 high-income European countries total €221 billion annually. Family caregivers carry a significant portion of this burden, providing an estimated €128 billion in unpaid care.
A large USC study of over 214,000 older adults across 14 countries found that controllable dementia risk factors such as low education and high blood pressure differ significantly from country to country. The study's findings suggest a one-size-fits-all approach to prevention may not be effective everywhere, and highlight the importanc...
A new $250,000 grant will support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction. The treatment aims to protect the brain from inflammation-related damage during and after sepsis, potentially preventing or slowing neurodegeneration and cognitive decline.
Researchers at ISSCR 2026 present interim clinical findings from the first Phase 1/2a trial of autologous iPSC-derived dopamine neuron precursor cells for Parkinson's disease. The approach uses each patient's own cells, and new genomic quality control methods ensure the manufactured cells are suitable for transplantation.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
The REGEN4HD study marks a significant milestone in the development of regenerative medicine approaches for Huntington's disease. The Phase 1b/2a trial enrolls early-stage symptomatic patients to evaluate safety and tolerability.
Researchers discovered that damaged myelin generates abnormal rhythms in the sleeping brain, linked to disruptions in brain circuit stability. This finding may help design non-invasive approaches to repair myelin during sleep, improving sleep quality in patients with MS and Alzheimer's disease.
The STEM-PD trial demonstrated the safety and feasibility of stem cell-derived dopaminergic cell transplantation in patients with moderate to advanced Parkinson's disease. The findings mark an important step in evaluating this approach as a potential treatment strategy for neurodegenerative diseases.
Glial cells play critical roles in determining brain recovery after TBI, and researchers have identified ways to selectively modulate their functions. The study highlights the importance of coordinated cellular behavior and suggests that targeting glial responses could lead to effective therapies.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
A new study describes a gene therapy strategy that uses the brain's glymphatic transport system to distribute engineered viral vectors throughout the brain. This approach enables preferential targeting of human glial cells while minimizing exposure to other cell types and organs, addressing two major challenges in neurological medicine.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Research suggests alcohol interacts with Alzheimer's-related brain circuits in distinct ways, depending on the type of pathological change. Alcohol reduced communication in amyloid-beta models but increased it in tau models, highlighting an important principle in biology.
Researchers found that KCL-286 enhances DNA repair and reduces neuronal inflammation in a mouse model of Alzheimer's disease. The drug activates the retinoic acid receptor-beta pathway, promoting the expression of certain repair genes.
Researchers at King's College London discovered a molecule linked to chronic inflammation disrupts brain neuron formation, highlighting a pathway with therapeutic potential for conditions like Alzheimer's disease and depression. High cytokine levels trigger an 'immune alert' state, reducing new nerve cell production.
Research found that Parkinson's disease triggers shared 'stress responses' but also differs between men and women at the cellular level, particularly in how glial cells manage energy and protect nerve connections. This discovery may lead to more personalized treatments for patients.
A new study links tire pollution to Alzheimer's disease through the exposure to 6PPD-quinone, a chemical formed from shaved-off tire particles. The researchers used computational methods to identify key genes that predict Alzheimer's disease and found strong binding of 6PPD-quinone to these genes.
Researchers propose a theoretical framework linking rubidium ion metabolic dysregulation to Parkinson's disease, highlighting the role of ionic homeostasis imbalance in neurodegeneration. Rubidium may serve as a potential biomarker and therapeutic target for early intervention.
Researchers at University of Arizona have found a promising new approach to slow fatal nerve disease ALS by blocking a small part of a key protein. The experimental drug XL20 protects nerve cells and reduces muscle weakness in mice and human nerve cells, representing a potential breakthrough.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.
Researchers have improved analysis of molecules linked to Alzheimer's disease by using higher magnetic fields, enabling the study of complex mixtures and identifying atomic-level clues. This finding could aid the development of future treatments for the disease.
Research suggests exposure to extreme heat and cold increases risk of emergency department visits among people with dementia. Extreme temperatures accelerate health events that would otherwise occur later, potentially leading to increased healthcare demand.
Researchers discovered that a brain protein called Arc helps spread toxic Tau from sick brain cells to healthy ones in mice. This finding suggests that targeting the spread of Tau could be a powerful tool to stop Alzheimer's disease progression. The study also highlights the potential protective role of Arc in early stages of the disease.
Research presented at the European Academy of Neurology Congress 2026 found that women with Parkinson's disease had significantly greater amyloid plaque burden and neuritic plaque density compared to men. The study suggests that women may be more susceptible to Alzheimer's-related changes in the brain.
Researchers identified karyoptosis as a key link between toxic protein accumulation and neuron death in neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The study found that targeting proteins acting as 'switches' in this pathway may slow or prevent cell death by karyoptosis.
Salk Institute researchers discovered chronoferroptosis, a chronic stress pathway in cells that causes neurons to become less resilient over time and more susceptible to neurodegeneration. Iron accumulation was found to lower the cells' defenses, making them more vulnerable to stressors.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
Researchers developed zebrafish model that reproduces key features of CADASIL, a hereditary disease causing brain damage and recurrent strokes. The study found progressive decline in cerebral blood flow and impaired learning ability, similar to human patients.
Researchers study blind Mexican cavefish to understand how evolution rewires the brain and shapes behavior. They found that cavefish become more active in light, a response believed to help them avoid predators.
Researchers at UCI Health have begun the world's first clinical trial for Huntington’s disease using neural stem cells. The phase 1b/2a trial aims to evaluate the safety and potential benefits of this innovative therapy, which could slow disease progression and reduce long-term care costs.
Researchers have found that cats show comparable patterns of brain deterioration as they age, similar to humans. This study, part of the Translating Time project, aims to unlock new insights into human ageing and disease by comparing cat and human brain development.
Insilico and SK Biopharmaceuticals collaborate on AI-powered drug discovery for neuroimmune disorders, aiming to accelerate discovery timelines and advance next-generation therapies. The partnership could be worth up to $2.5 billion, with Insilico receiving upfront and milestone payments.
Researchers discovered blood RNA biomarkers that could support earlier diagnosis of Alzheimer's disease, potentially reducing the need for invasive tests. They identified brain-specific markers in circulating blood nanoparticles, which may offer a minimally invasive approach for diagnosing the progressive neurodegenerative disease.
Researchers used AI to identify hidden peptides called prionins in prion and prion-like proteins, which can kill bacteria and may hold the key to treating drug-resistant infections. The study suggests that these proteins, commonly associated with neurodegenerative diseases, contain molecular features linked to immune defense.
A new research project will study the effect of immune cell aging on Parkinson's disease risk and progression. The team aims to identify individuals at greater risk for Parkinson's disease and develop targeted treatments.
Researchers at University of Michigan Health have implanted the first wireless brain-computer interface (BCI) to restore communication in a patient with motor neuron disease. The study, called Connect-One Early Feasibility Study, aims to assess the device's long-term safety and effectiveness in synthesizing text and speech.
The University of Michigan has successfully implanted the first-in-human Paradromics wireless brain-computer interface, designed to restore communication for patients with difficulty speaking. The clinical trial will focus on the device's long-term safety and assess its ability to restore communication through synthesized text and speech.
Researchers have identified an experimental molecule called OLE that can restore part of the brain's protective function against Alzheimer's disease. The compound helps microglia enclose and contain beta-amyloid plaques, reducing their size and toxicity.
Researchers developed LiON, a fluorescent reporter that visualizes biologically active iron and oxygen inside living cells. The tool revealed striking differences in iron and oxygen distribution across organs and cells, offering new opportunities to study diseases like cancer, liver disorders, and neurodegenerative conditions.
Researchers found that patients with Medicare Advantage insurance were more likely to receive certain types of stroke-preventing care and recover faster from strokes. In contrast, patients on traditional Medicare received more intensive post-stroke care and rehabilitation.
A new study found that intranasal davunetide reaches the brain in higher amounts in female mice when estrogen peaks, with similar results seen in healthy adults. The findings suggest earlier trials mixing males and females may have obscured the true effects of the drug.
A new study revealed that retinal photographs can accurately predict many common risk factors associated with developing Alzheimer's disease. The AI model identified regions of the retina linked to Alzheimer's risk factors, such as arteries and optical nerve, and predicted lifestyle factors like smoking and alcohol use.
Researchers at Indiana University are using artificial intelligence and machine learning to discover new treatments for Alzheimer's disease. The team hopes to create AI-driven tools that can efficiently screen billions of compounds and prioritize those most likely to interact with disease-related targets.
A new study investigates whether obesity contributes to faster brain aging and earlier memory decline. Researchers found that high K63 polyubiquitination levels in young obese rats matched those seen in older brains, suggesting a connection between obesity-induced and age-related memory loss.
Researchers at Nagoya University developed an AI tool, DiSPAH, to estimate ALS disease progression speed and identify muscle decline patterns. The study found six distinct patterns of disease progression among patients, with some experiencing rapid deterioration while others declined slowly.
Researchers found a copper-based compound significantly reduces toxic Alzheimer's proteins and improves long-term spatial memory in laboratory experiments. The treatment repairs the brain's waste-clearing pump, allowing it to clear out trapped toxic proteins and reduce amyloid buildup by 42%.